TRI ACT 1

TRI ACT 1 contains Glimepiride 1 mg + Metformin 500 mg (SR) + Pioglitazone 15 mg, a balanced triple-action therapy for managing type 2 diabetes. Glimepiride helps stimulate insulin secretion, Metformin reduces liver glucose production and improves insulin sensitivity, while Pioglitazone enhances glucose uptake in body tissues. This combination supports better blood sugar control and helps maintain stable long-term glycemic management.